Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
John H. Strickler, Andrea Cercek, Salvatore Siena et al. · The Lancet Oncology · 2023
Cited by 254 works. doi:10.1016/s1470-2045(23)00150-x
Authors
- John H. Strickler
- Andrea Cercek
- Salvatore Siena
- Thierry André
- Kimmie Ng
- Eric Van Cutsem
- Christina Sing-Ying Wu
- Andrew Scott Paulson
- Joleen Marie Hubbard
- Andrew L. Coveler
- Christos K Fountzilas
- Adel Kardosh
- Pashtoon Murtaza Kasi
- Heinz‐Josef Lenz
- Kristen Keon Ciombor
- Elena Élez
- David Lawrence Bajor
- Chiara Cremolini
- Federico Sanchez
- Michael Stecher
References
- Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
- Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
- A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
- Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
- Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
- NCCN Guidelines Insights: Rectal Cancer, Version 6.2020
- The immune system and response to HER2-targeted treatment in breast cancer
- Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial